Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab for Graves disease with pretibial myxedema
ChiCTR2500110605Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Graves' disease, Graves' dermopathy and Graves Orbitopathy (GO) comparing Teprotumumab with Placebo (2 arms). Primary endpoint: Changes of pretibial myxedema. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
teprotumumab
03
Conditions
Graves' diseaseGraves' dermopathyGraves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2500110605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110605.